ACHN News Alert Achillion Pharmaceuticals (ACHN) 13.33 01/03/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 2:18 PM

Achillion Pharmaceuticals (ACHN) 13.33 $ACHN

The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 91.26 (-0.46), TTPH: 39.72 (+0.01), AVNR: 16.94 (-0.01), SWKS: 73.32 (+0.61), CMRX: 41.78 (+1.52), ACHN: 13.33 (+1.08), HA: 25.27 (-0.78), RCPT: 124.81 (+2.30), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)

One Reason Achillion Pharmaceuticals (ACHN) Stock is Rising Today
at The Street - Fri Jan 02, 11:18AM CST
Shares of Achillion Pharmaceuticals (ACHN) were up Friday after Roth Capital analyst Peter Kolchinsky identified the company as an attractive takeover target.
ACHN: 13.33 (+1.08)

Biotech Stocks 2014: The Best, Worst and Fastest-Growing
at The Street - Fri Jan 02, 7:33AM CST
Once again, biotech stocks greatly outperformed the broader market in 2014.
BLUE: 91.26 (-0.46), OVAS: 45.83 (+1.61), ACHN: 13.33 (+1.08), RCPT: 124.81 (+2.30), AGIO: 109.76 (-2.28)

3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 30, 9:41AM CST
Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
JNJ: 104.52 (-0.05), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45)

DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially
SA Editors - Seeking Alpha - Tue Dec 30, 6:05AM CST
Today we present the fifth piece in Seeking Alpha's Positioning for 2015 series. This year we have once again asked experts on a range of different asset classes and investing strategies to offer their vision for the coming year and beyond....
BIIB: 342.01 (+2.56), SPY: 205.43 (-0.11), PTLA: 28.51 (+0.19), PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), MRK: 57.19 (+0.40), EW: 127.72 (+0.34), IBB: 306.34 (+2.99), HQH: 31.87 (+0.38), REGN: 410.16 (-0.09), CELG: 113.52 (+1.66)

Could These Tiny Biotech Stocks Double in 2015?
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 30, 5:50AM CST
Biotechnology's mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them -- but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there...
PTLA: 28.51 (+0.19), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), PFE: 31.33 (+0.18), OPHT: 45.60 (+0.73), BMY: 59.51 (+0.48), REGN: 410.16 (-0.09), NVS: 92.25 (-0.41)

The Zacks Analyst Blog Highlights: Tekmira, Chimerix, Gilead, AbbVie, Achillion Pharmaceuticals, Agios Pharmaceuticals, PTC Therapeutics and Tetraphase Pharmaceuticals
PR Newswire - Mon Dec 29, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tekmira (Nasdaq:TKMR-Free Report), Chimerix (Nasdaq:CMRX-Free Report), Gilead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Agios Pharmaceuticals, Inc. (Nasdaq:AGIO-Free Report), PTC Therapeutics, Inc. (Nasdaq

TCT-Free Report) and Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH-Free Report).
ACHN: 13.33 (+1.08), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)

Should AbbVie Inc. and Gilead Sciences, Inc. Fear This Biotech Instead of Each Other?
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 28, 10:11AM CST
Source: Gilead Sciences via Google Maps. Gilead Sciences shares tumbled following the approval of AbbVie 's new hepatitis C drug Viekira Pak, but both companies may find that their longer-term battle isn't with each other, but with Achillion...
ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45)

Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 35.18 (+0.11), CYTK: 7.37 (-0.64), JNJ: 104.52 (-0.05), ESRX: 84.65 (-0.02), ALNY: 97.77 (+0.77), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), ANIK: 39.76 (-0.98)

Most active Nasdaq-traded stocks
AP - Fri Dec 26, 12:21PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
ATOS: 1.40 (-0.03), GILD: 94.91 (+0.65), FB: 78.45 (+0.43), ACHN: 13.33 (+1.08), ARCP: 9.27 (+0.22), INTC: 36.36 (+0.07), GRPN: 8.02 (-0.24), AAPL: 109.33 (-1.05)

Nasdaq stocks posting largest percentage increases
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
KNDI: 13.04 (-0.97), WATT: 11.38 (+0.42), ACHN: 13.33 (+1.08), PLMT: 17.02 (+0.32)

February 2015 Options Now Available For Achillion Pharmaceuticals
at The Street - Wed Dec 24, 11:30AM CST
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the February 2015 expiration.
ACHN: 13.33 (+1.08)

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 342.01 (+2.56), VRTX: 123.07 (+4.27), CBST: 100.76 (+0.11), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), IMGN: 6.49 (+0.39), ABBV: 65.89 (+0.45)

Premarket Gainers / Losers as of 9:10 ET
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:12AM CST

NVGS: 20.19 (-0.87), ACHN: 13.33 (+1.08), ADMS: 17.49 (+0.12), DGLY: 15.46 (+0.14)

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.52 (-0.05), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), ENTA: 50.45 (-0.40)

Achillion set for gap up at the open
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:01AM CST

ACHN: 13.33 (+1.08)

Achillion Gains on Positive Results from its HCV Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:00PM CST
Achillion Pharmaceuticals (ACHN) gained more than 9% after announcing encouraging results from its HCV candidates.
JNJ: 104.52 (-0.05), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), AMGN: 159.89 (+0.60)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Americas Cardroom's Poker Series Hits $7.2M Haul

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...